Pharmacist-led education that improves asthma control
Asthma medicines only deliver their intended benefit when patients use the correct device, dose and inhalation technique. Pharmacist-led education can improve daily inhaler use while reducing avoidable asthma exacerbation rates, particularly when education is combined with medication review, action-plan support and follow-up. The intervention is especially valuable because pharmacists often see patients during repeat dispensing, when symptoms may be poorly controlled or device technique has never been checked.
Effective education extends beyond a brief demonstration. It identifies the inhaler in use, corrects device-specific errors, confirms that the patient can follow their written asthma action plan, and connects ongoing care with the patient’s general practitioner. In Australia, this work sits within a distinctive system of subsidised medicines, accessible community pharmacies and state-based variations in healthcare delivery.
The Australian asthma context
More than 2.5 million Australians live with asthma, with attacks linked to factors including viral infections, pollen, smoke, cold weather and poor adherence to preventer medicines. Melbourne and Sydney experience substantial seasonal pollen, while smoke events can affect communities across eastern Australia. Many people also buy pharmacy-only reliever medicines without receiving a full technique review or an asthma assessment.
| Inhaler format | Common error | Key teaching point | When review is useful |
|---|---|---|---|
| Pressurised metered-dose inhaler with spacer | Shaking, poor hand–mouth coordination or breathing too quickly | Actuate once and take slow, deep breaths through the spacer | At diagnosis, device changes and after an exacerbation |
| Pressurised metered-dose inhaler without a spacer | Holding the inhaler too far from the mouth | Coordinate pressing and breathing, or discuss a spacer | Before purchasing a new device and during technique checks |
| Dry powder inhaler | Taking a slow, shallow breath | Use a fast, deep inhalation as directed by the manufacturer | Whenever the device or technique changes |
| Soft-mist inhaler | Inhaling too forcefully or missing the breath | Seal the lips and inhale steadily and deeply | Initial training and medication reviews |
Australian geography creates additional barriers. People in regional New South Wales, Queensland or Western Australia may travel considerable distances for medical review, making community pharmacies and telehealth important access points. Culturally safe education should also account for language, health literacy, smoking, vaping, occupational exposures and the cost of spacers or repeat prescriptions.
Most inhaled medicines are available through the Pharmaceutical Benefits Scheme under the National Health Act 2013, and the Therapeutic Goods Administration regulates the devices. However, subsidy does not automatically resolve technique errors, affordability concerns or fragmented prescribing. The National Asthma Strategy and National Asthma Council Australia guidance support regular technique assessment, written action plans and coordinated care, while state and territory rules determine where pharmacists can undertake additional prescribing roles.
How pharmacist-led education changes technique
A useful consultation begins with the patient demonstrating their current method rather than simply listening to a description. The pharmacist can then provide individual feedback using a device-specific checklist. This teach-back approach lets the patient repeat the technique, gives the pharmacist an opportunity to correct errors immediately and creates a record of what was practised.
The distinction between inhaler types is essential. A person who has learned to breathe slowly through a metered-dose inhaler with a spacer may inhale a dry powder inhaler incorrectly by using the same slow technique. Conversely, a fast inhalation used for a dry powder device is unsuitable for some pressurised metered-dose inhalers. Education should therefore teach the correct method for the actual product and its instructions, rather than applying one technique to every inhaler.
Education works best when it addresses barriers as well as mechanics. The pharmacist can check whether scripts are being collected, whether the patient understands the difference between preventer and reliever medicines, and whether cost, side effects or confusion are affecting use. For patients using an inhaled corticosteroid–formoterol AIR MART regimen, the action plan should clearly identify when it is to be used and whether a separate preventer inhaler is also required. Pharmacists can access professional practice resources to extend their learning beyond the technical elements of device training.
What changes in exacerbation rates
Research and service evaluations generally show that pharmacist-led education improves inhaler technique, knowledge and confidence. Some studies also report fewer oral corticosteroid courses, emergency department presentations or hospital admissions. The reduction in asthma exacerbation rates is plausible because correct administration improves delivery of preventer medicine, while action-plan support helps patients recognise deterioration and respond early.
The size of the effect depends on the intervention. One-off instruction during a single dispensing visit often produces short-term improvement that fades as old habits return. Longer-term outcomes are more likely when education is repeated, linked with medication optimisation and supported by a clinical review. Education cannot compensate for unsuitable prescribing, an inadequate regimen, continued smoke exposure or poor access to follow-up, so outcome claims should consider these other influences.
Measurement should distinguish between process and clinical outcomes. Technique scores and spacer use indicate whether education was delivered, while oral corticosteroid prescribing, reliever use, unscheduled healthcare contacts and hospital admissions provide stronger signals about exacerbations. Results should also be stratified by age, language, location and socioeconomic circumstances, since a programme that improves average scores may still leave groups experiencing the greatest barriers with limited benefit.
Collaboration adds another layer to safe education. Some patients managing asthma also have anxiety, depression or other conditions requiring psychotropic medicines. A psychotropic REMS overview illustrates how risk-management programmes structure education and follow-up, although those US FDA requirements do not apply in Australia. The useful principle is the need for clear communication, documented responsibilities and patient-centred review across the healthcare team.
Building an effective local program
Community pharmacies can design education around brief, repeatable contacts rather than occasional lengthy appointments. A two-minute technique check at every repeat dispensing may be more sustainable than a comprehensive review that only occurs when the patient asks. Higher-risk patients, including those recently hospitalised, prescribed multiple inhalers or using frequent reliever medicines, can be prioritised for a longer consultation.
The physical environment influences education as well. A counselling screen visible from the street may expose patient information, particularly when videos are displayed near the pharmacy counter. A guide to a layered privacy screen demonstrates how shrubs and grasses can block sightlines, offering a practical principle for pharmacies considering open-screen displays. Private consultation areas, headphone use and small-group education sessions can further protect confidentiality.
Core components of a technique session
- Match the method to the inhaler, including whether a spacer or holding chamber is required.
- Ask the patient to demonstrate activation, inhalation, breath-holding and when to rinse after using relevant medicines.
- Use teach-back to confirm that the patient can explain what the preventer and reliever medicines do.
- Review the written action plan, warning signs and access to scripts, spacers and medical review.
Outcome measures for follow-up
- Record device-specific technique competency at baseline and at follow-up.
- Track preventer use, reliever frequency and access to a current written action plan.
- Monitor oral corticosteroid courses, emergency department visits and hospital admissions.
- Compare outcomes across locations and patient groups to identify inequities in access.
These components make the intervention more than a demonstration. They create a cycle in which the pharmacist identifies an error, corrects it, checks whether the patient can implement the change and confirms whether asthma control improves. Consistent documentation also gives the patient’s general practitioner useful information and supports continuity when care is shared.
Turning education into routine care
A practical workflow begins when a patient presents with an inhaler or asks for repeat medication. The pharmacist checks the device, observes technique, updates the medication record and provides brief instruction. Any discrepancy is documented and, where appropriate, communicated to the prescriber. Patients who require structured education can be referred to a trained asthma educator or offered a longer private review.
Pharmacy leaders can support the workflow with staff training, protected consultation time, device demonstration equipment and agreed escalation pathways. Local health services can incorporate community pharmacists into post-discharge follow-up, while general practices can share relevant information under existing privacy and consent arrangements. State-funded pharmacist prescribing pathways may provide additional options in some jurisdictions, but service availability and authority differ across Australia.
Make inhaler technique an observable part of every asthma-related pharmacy encounter. Ask patients to demonstrate what they do, correct the first misunderstanding, link the change to their action plan and arrange the next point of review. Consistent education at the point of dispensing can strengthen preventer use, support earlier responses to worsening symptoms and reduce avoidable asthma exacerbations across the community.